"Oman Pharmaceuticals & Healthcare Report Q4 2012" Now Available at Fast Market Research
BMI View: Historically, Oman's pharmaceutical market has been dominated by patented drugs set at low prices imposed by the government's strict pricing regime. However, BMI believes that due to the current and ongoing patent cliff and Indian generic drugmakers pursuing the local market, focus will shift from patented drugs to generic over the long term. While this will boost overall local production, the market will remain heavily reliant on imports. Despite a top-class healthcare system, ageing population and rise in...
View full press release